A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

This trial is testing a new drug called BP1002 in adults with relapsed or treatment-resistant acute myeloid leukemia (AML) who have no remaining effective options. BP1002 works by targeting a protein that helps cancer cells survive. **You may be eligible if...** - You are 18 or older with AML that has come back or failed to respond to available treatments - You are in reasonably good health (ECOG 0–2) - Your liver and kidney function are within acceptable ranges - You are willing to use effective contraception during and after treatment **You may NOT be eligible if...** - You have acute promyelocytic leukemia (APL) or chronic myeloid leukemia - You have leukemia that has spread to the brain and requires direct spinal treatment - You have recently received cancer treatment (within 14 days) - You are pregnant or breastfeeding - You have had a heart attack, stroke, or severe heart disease within the past 6 months - You have uncontrolled seizures Talk to your doctor to see if this trial is right for you.